Evidence map›Paper›PMID 33290844›Full record

SynthesisSeminars in cancer biology2022

Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy.

Jia Wu, Aaron T Mayer, Ruijiang Li

Abstract readSystematic Review
In one paragraph

Synthesis in Seminars in cancer biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jia WuDepartment of Imaging Physics, MD Anderson Cancer Center, Texas, 77030, USA; Department of Thoracic/Head & Neck Medical Oncology, MD Anderson Cancer Center, Texas, 77030, USA. Electronic address: JWu11@mdanderson.org.
Aaron T MayerDepartment of Bioengineering, Stanford University, Stanford, California, 94305, USA; Department of Radiology, Stanford University, Stanford, California, 94305, USA; Molecular Imaging Program at Stanford, Stanford University, Stanford, California, 94305, USA; BioX Program at Stanford, Stanford University, Stanford, California, 94305, USA.
Ruijiang LiDepartment of Radiation Oncology, Stanford University, Stanford, California, 94305, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Imaging and circulating DNA markers to assess early response and predict treatment failure patterns in lung cancerR01CA233578 · NCI · STANFORD UNIVERSITY · PI DIEHN, MAXIMILIAN, LI, RUIJIANG · 2019 to 2023
$2.7M
Multiregional imaging phenotypes and molecular correlates of aggressive versus indolent breast cancerR01CA222512 · NCI · STANFORD UNIVERSITY · PI LI, RUIJIANG · 2018 to 2023
$2.4M
MRI-Based Radiation Therapy Treatment PlanningR01CA193730 · NCI · STANFORD UNIVERSITY · PI LI, RUIJIANG · 2016 to 2020
$1.8M
QUANTITATIVE IMAGING BIOMARKERS OF TREATMENT RESPONSE AND PROGNOSIS IN BREAST CANCERR00CA218667 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WU, JIA · 2020 to 2022
$747k
Quantitative Imaging Biomarkers of Treatment Response and Prognosis in Breast CancerK99CA218667 · NCI · STANFORD UNIVERSITY · PI WU, JIA · 2018 to 2019
$322k
NCI NIH HHS K99 CA218667NCI NIH HHS P30 CA016672NCI NIH HHS R00 CA218667NCI NIH HHS R01 CA193730NCI NIH HHS R01 CA222512NCI NIH HHS R01 CA233578
6 · The paper itself

Abstract

Radiological imaging is an integral component of cancer care, including diagnosis, staging, and treatment response monitoring. It contains rich information about tumor phenotypes that are governed not only by cancer cellintrinsic biological processes but also by the tumor microenvironment, such as the composition and function of tumor-infiltrating immune cells. By analyzing the radiological scans using a quantitative radiomics approach, robust relations between specific imaging and molecular phenotypes can be established. Indeed, a number of studies have demonstrated the feasibility of radiogenomics for predicting intrinsic molecular subtypes and gene expression signatures in breast cancer based on MRI. In parallel, promising results have been shown for inferring the amount of tumor-infiltrating lymphocytes, a key factor for the efficacy of cancer immunotherapy, from standard-of-care radiological images. Compared with the biopsy-based approach, radiogenomics offers a unique avenue to profile the molecular makeup of the tumor and immune microenvironment as well as its evolution in a noninvasive and holistic manner through longitudinal imaging scans. Here, we provide a systematic review of the state of the art radiogenomics studies in the era of immunotherapy and discuss emerging paradigms and opportunities in AI and deep learning approaches. These technical advances are expected to transform the radiogenomics field, leading to the discovery of reliable imaging biomarkers. This will pave the way for their clinical translation to guide precision cancer therapy.

Indexed as

Breast NeoplasmsTumor MicroenvironmentBiomarkers, TumorFemaleGenomicsHumansImmunotherapyLymphocytes, Tumor-InfiltratingBiomarkers, TumorImmunotherapyMachine learningRadiogenomicsRadiomicsTumor immune microenvironment

Identifiers

PMID33290844
PMCPMC8319834

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.